Syndax Pharmaceuticals
Syndax Pharmaceuticals is dedicated to developing innovative therapies for cancer patients, focusing on areas such as acute leukemias, chronic graft-versus-host disease, and other focus areas. They aim to improve patient outcomes through their pipeline of clinical studies and products.
Industries
Nr. of Employees
medium (51-250)
Syndax Pharmaceuticals
Patents
Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody
US-12168054-B2
View DetailsCombination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer
US-11324822-B2
View Details
Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody
US-12168054-B2
View DetailsCombination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer
US-11324822-B2
View DetailsProducts
Therapeutic candidates for hematologic malignancies
Investigational therapeutic agents in development targeting blood cancers and related disorders; portfolio includes multiple clinical-stage candidates.
Therapeutic candidates for hematologic malignancies
Investigational therapeutic agents in development targeting blood cancers and related disorders; portfolio includes multiple clinical-stage candidates.
Services
Execution and management of multicenter clinical trials for investigational therapeutics in oncology.
Provision and administration of expanded access programs to supply investigational therapies outside of formal trials.
Patient-directed information and contact resources to support trial enrollment and program inquiries.
Execution and management of multicenter clinical trials for investigational therapeutics in oncology.
Provision and administration of expanded access programs to supply investigational therapies outside of formal trials.
Patient-directed information and contact resources to support trial enrollment and program inquiries.
Expertise Areas
- Clinical trial management
- Expanded access / compassionate use programs
- Oncology drug development
- Hematologic malignancies (acute myeloid leukemia, KMT2A-rearranged, NPM1-mutant; chronic graft-versus-host disease)
Key Technologies
- Clinical trial implementation
- Expanded access program administration
- Oncology therapeutic development
- Preclinical-to-clinical pipeline management